These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3536397)

  • 1. [Dose-dependent serum concentration of ISDN and its metabolites following administration of ISDN-retard. Studies under steady-state conditions].
    Loew D; Deuster U; Burkhardt H; Rietbrock N
    Dtsch Med Wochenschr; 1986 Nov; 111(48):1834-7. PubMed ID: 3536397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
    Rietbrock N; Knoll J; Merz PG; Menke G
    Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
    Geigenberger A; Degen J; Maier-Lenz H
    Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
    Menke G; Schnellhammer R; Rietbrock N
    Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
    Keller-Stanislawski B; Marschner JP; Rietbrock N
    Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the production of methemoglobin during high-dose treatment with isosorbide dinitrate or isosorbide 5-mononitrate.
    Schneider W; Stahl B; Kaltenbach M; Bussmann WD
    Arzneimittelforschung; 1984; 34(12):1779-82. PubMed ID: 6543314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term tolerance and effect of isosorbide-5-mononitrate in comparison to isosorbide dinitrate (ISDN retard) in patients with coronary disease].
    Smolarz A; Seeliger S; Glocke M
    Med Welt; 1981 Apr; 32(14A):548-53. PubMed ID: 6787385
    [No Abstract]   [Full Text] [Related]  

  • 9. Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.
    Schneider W; Menke G; Heidemann R; Satter P; Kaltenbach M; Rietbrock N
    Eur J Clin Pharmacol; 1990; 38(2):145-7. PubMed ID: 2338111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plasma levels of isosorbide dinitrate and its metabolites during intravenous infusion in surgical patients--effect of preoperative administration of isosorbide dinitrate].
    Murakawa T; Hashimoto Y; Sato T; Takagi H; Kushikata T; Araki I; Kou H; Kimura F; Matsuki A
    Masui; 1993 Feb; 42(2):225-32. PubMed ID: 8437354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
    Kogi K; Tanaka O; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
    Döring G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S74-81. PubMed ID: 1282180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
    Kumagae H; Koiwaya Y; Tanaka K
    Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.
    Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G
    Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isosorbide dinitrate bioavailability, kinetics, and metabolism.
    Straehl P; Galeazzi RL
    Clin Pharmacol Ther; 1985 Aug; 38(2):140-9. PubMed ID: 4017416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease.
    Jørgensen LH; Thaulow E; Bredesen J; Refsum HE
    Clin Cardiol; 2000 Jun; 23(6):427-32. PubMed ID: 10875033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
    Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effects of oral isosorbide-5-mononitrate and dinitrate in ischemic heart failure.
    Rabinowitz B; Hod H; Chouraqui P; Rath S; Agranat O; Neufeld HN
    Clin Cardiol; 1987 Oct; 10(10):603-8. PubMed ID: 3665218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-effect relationship amongst three different sustained-release forms of isosorbide 5-mononitrate in patients with coronary artery disease.
    Kenedi P; Gathmann-Lewik U
    Cardiology; 1987; 74 Suppl 1():29-33. PubMed ID: 3300975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.